BLA 103705 · Genentech
Rituxan
Rituximab · Intravenous · CD20-directed Cytolytic Antibody
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Nov 26, 1997
Approved uses
18
Original approval plus efficacy supplements
Registered trials
2,564
526 Phase 3, 340 recruiting
FAERS reports
214,105
191,594 serious, 37,921 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Fatal infusion-related reactions within 24 hours of RITUXAN infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue RITUXAN infusion for severe reactions ( 5.1 ). Severe mucocutaneous reactions, some with fatal outcomes ( 5.2 ). Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death ( 5.3 ). Progressive multifocal leukoencephalopathy (PML) resulting in death ( 5.4 ). Infusion-Related Reactions RITUXAN administration...
What it is approved for
From the label in effect Jan 6, 2025.
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe...
Mechanism: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 2, 2021 Supplement 5465 · Efficacy · priority review OrphanLabelMedication GuideLetter
- Aug 28, 2020 Supplement 5460 · Efficacy LetterLabel
- Sep 27, 2019 Supplement 5457 · Efficacy · priority review OrphanLetterLabelMedication Guide
- Jan 25, 2019 Supplement 5454 · Efficacy OrphanLabelLetter
- Oct 18, 2018 Supplement 5451 · Efficacy OrphanLabelLetter
- Jun 7, 2018 Supplement 5450 · Efficacy · priority review OrphanLabelLetter
- Oct 19, 2012 Supplement 5367 · Efficacy OrphanLabelLetter
- Apr 19, 2011 Supplement 5344 · Efficacy · priority review OrphanReviewLetterLabel
- Jan 28, 2011 Supplement 5332 · Efficacy OrphanLetterLabel
- Feb 18, 2010 Supplement 5312 · Efficacy · priority review OrphanLabelLetter
- Feb 18, 2010 Supplement 5311 · Efficacy · priority review OrphanLabelLetter
- Oct 16, 2009 Supplement 5299 · Efficacy LabelLetter
- Jan 25, 2008 Supplement 5256 · Efficacy LabelLetter
- Sep 29, 2006 Supplement 5231 · Efficacy · priority review OrphanLabel
- Sep 29, 2006 Supplement 5230 · Efficacy · priority review OrphanLabelLetter
- Feb 28, 2006 Supplement 5211 · Efficacy · priority review LetterLabel
- Feb 10, 2006 Supplement 5209 · Efficacy · priority review OrphanLabel
- Nov 26, 1997 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewOther Important Information from FDA
2 products under this application
- RITUXAN · RITUXIMAB 500MG/50ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- RITUXAN · RITUXIMAB 100MG/10ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rituximab" as an intervention, any sponsor and status, largest first.
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesPivotal-lookingActive, not recruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT05879419 · 2,005 participants (planned) · Start May 23, 2023 · Primary completion Dec 1, 2025
Drug: Recombinant Herpes Zoster Vaccine (RZV) · For: Rheumatoid Arthritis; Spondylitis, Ankylosing; Spondyloarthritis and 8 more
Sites: São Paulo, Brazil
- Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaPivotal-lookingCompleted
German High-Grade Non-Hodgkin's Lymphoma Study GroupAcademic, hospital or other
NCT00052936 · 1,506 participants · Start Jan 2001 · Primary completion Aug 5, 2010
Drug: filgrastim; rituximab and 5 more · For: Lymphoma
Sites: Aachen, Germany; Amberg, Germany; Ansbach, Germany · 174 sites in all
- HD18 for Advanced Stages in Hodgkins LymphomaPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT00515554 · 1,500 participants · Start May 2008 · Primary completion Jul 2019
Drug: Rituximab; BEACOPP escalated · For: Hodgkins Lymphoma
Sites: Cologne, Germany
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01287741 · 1,418 participants · Start Jul 26, 2011 · Primary completion Apr 29, 2016
Drug: Rituximab; Obinutuzumab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 235 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01332968 · 1,401 participants · Start Jul 6, 2011 · Primary completion Feb 1, 2016
Drug: Obinutuzumab; Cyclophosphamide and 5 more · For: Non-Hodgkin's Lymphoma
Sites: Springdale, Arkansas; Irvine, California; Post Falls, Idaho · 183 sites in all
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasPivotal-lookingStatus unknown
Jurgen BarthAcademic, hospital or other
NCT00877214 · 1,272 participants · Start Apr 1, 2009 · Primary completion Dec 2024
Drug: Rituximab; Rituximab / observation · For: Follicular Lymphomas; Immunocytomas; Marginal Zone Lymphomas and 3 more
Sites: Giessen, Germany
- Primary Rituximab and MaintenancePivotal-lookingCompleted
Lymphoma Study AssociationAcademic, hospital or other
NCT00140582 · 1,217 participants · Start Dec 2004 · Primary completion May 2007
Drug: Rituximab · For: Follicular Lymphoma
Sites: Buenos Aires, Argentina; Melbourne, Australia; Ghent, Belgium · 24 sites in all
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use41,722
- drug ineffective34,408
- rheumatoid arthritis20,327
- pain17,935
- fatigue17,483
- rash13,683
- arthralgia13,466
- pneumonia13,256
- infusion related reaction12,870
- drug intolerance12,675
- joint swelling12,000
- pyrexia11,912
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 508 |
| 2005 | 739 |
| 2006 | 724 |
| 2007 | 1,256 |
| 2008 | 1,417 |
| 2009 | 2,038 |
| 2010 | 2,486 |
| 2011 | 3,186 |
| 2012 | 4,694 |
| 2013 | 4,805 |
| 2014 | 5,019 |
| 2015 | 5,951 |
| 2016 | 6,768 |
| 2017 | 11,206 |
| 2018 | 12,326 |
| 2019 | 14,980 |
| 2020 | 20,539 |
| 2021 | 18,597 |
| 2022 | 21,328 |
| 2023 | 20,221 |
| 2024 | 24,171 |
| 2025 | 18,885 |
| 2026 | 12,260 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rituxan (Rituximab)
2024 spending
$38.7M
Beneficiaries
1,499
3,244 claims
Per beneficiary
$25,831
$91.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,977,642 |
| 2021 | $46,933,066 |
| 2022 | $46,055,636 |
| 2023 | $39,322,014 |
| 2024 | $38,719,960 |
Part B: Rituxan (Rituximab) · HCPCS J9312
2024 spending
$437M
Beneficiaries
22,261
65,209 claims
Per beneficiary
$19,630
2024 ASP limit $78.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,295,906,200 |
| 2021 | $765,560,206 |
| 2022 | $579,169,245 |
| 2023 | $483,730,047 |
| 2024 | $436,980,635 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial.
Isaka Y, Sakaguchi Y, Shinzawa M, et al. · JAMA 2025 · Randomized Controlled Trial, Multicenter Study
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.